At Frontiers Health, the future of pharma is actively being shaped. In a compelling plenary fireside chat, Alessandro de Luca, Head of Digital Enterprise Solutions and Group CIO, Merck Group and Emre Özcan, SVP, Global Head of Digital Health and Devices, Merck Group, will explore how the convergence of science and technology is redefining the pharmaceutical landscape.

Pharma is at a pivotal inflection point. The integration of advanced scientific research, digital technologies, and real-world data is revolutionizing how treatments are developed, delivered, and experienced. At the heart of this transformation lie digital therapeutics (DTx)—evidence-based interventions that are shifting pharma’s role from a traditional drug provider to a holistic therapy partner focused on continuous, measurable outcomes.

The fireside chat, taking place on November 12 in the afternoon plenary session, will delve into how digital innovation is reshaping:

• Clinical development through smarter, data-driven trial designs
• Commercial models that prioritize value-based care
• Patient engagement with personalized, tech-enabled experiences

De Luca and Özcan will highlight both the opportunities and challenges of integrating digital therapeutics alongside pharmacological treatments. From regulatory hurdles to interoperability, the path forward requires collaboration, agility, and a shared vision for hybrid care models that combine the best of both worlds.

At Frontiers Health we’ve been setting the stage for a future where personalized, hybrid therapies become the norm—empowering patients and redefining outcomes across the healthcare continuum.

Stay tuned for more insights from Frontiers Health 2025 as we continue to spotlight the leaders and innovations driving the future of health.

Get your FH25 pass now — spots are going fast!